The incidence of multiple myeloma is forecast to total 40,885 cases across the seven major pharmaceutical markets in 2007. Current drug therapy is planned around stem cell transplantation. The recent approval of three new agentsThalomid (thalidomide; Celgene), Revlimid (lenalidomide; Celgene) and Velcade (bortezomib; Millenium/Johnson & Johnson)has significantly advanced treatment.
Scope
Multiple myeloma epidemiology, disease features and progress in current treatment
Remaining unmet needs in the treatment of multiple myeloma
Research and analysis of the multiple myeloma pipeline with in-depth clinical and commercial assessment of Phase III drug candidates
Stakeholder opinions based on qualitative interviews with key opinion leaders from the US and EU
Highlights
The approval of three new agents, Thalomid (thalidomide; Celgene), Revlimid (lenalidomide; Celgene) and Velcade (bortezomib; Millenium/Johnson & Johnson), has significantly changed the MM treatment approach for both newly diagnosed and relapsed/refractory disease. Despite the recent advances in treatment, MM remains largely incurable as disease relapse is inevitable. There remains a strong need for more efficacious and tolerable drugs that affect new therapeutic targets and enhance patient outcomes. There is great opportunity for novel agents to enter the myeloma market as patients often require multiple lines of therapy. Furthermore, the major approach to myeloma drug therapy is the use of combined regimens. A drug that shows potential synergistic activity with other approved or emerging drugs would be well received.
Reasons to Purchase
Gain an insight into the epidemiology trends and disease characteristics of multiple myeloma
Analyze the current status of multiple myeloma treatment and consider the remaining unmet needs
Acquire a detailed appreciation and impartial perspective of the multiple myeloma pipeline and identify the key products in late-phase development.
